DOCSLIB.ORG

Hip and Knee Replacement

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hip and Knee Replacement 9. HEALTH CARE ACTIVITIES Hip and knee replacement Hip and knee replacements are some of the most frequently obesity rates in OECD countries. For example, in the United performed and effective surgeries worldwide. The main States, the prevalence of knee osteoarthritis has more than indication for hip and knee replacement (joint replacement doubled since the mid-20th century (Wallace et al., 2017[4]). surgery) is osteoarthritis, which leads to reduced function Most OECD countries show increasing trends of varying and quality of life. degrees, but Ireland and Luxembourg show slower growth Osteoarthritis is a degenerative form of arthritis than the average, these are also the only OECD countries to characterised by the wearing down of cartilage that show a decrease in hip replacements rates from 2007. cushions and smooths the movement of joints – most commonly for the hip and knee. It causes pain, swelling and stiffness resulting in a loss of mobility and function. Definition and comparability Osteoarthritis is one of the ten most disabling diseases in developed countries. Worldwide, estimates show that 10% Hip replacement is a surgical procedure in which the of men and 18% of women aged over 60 years have hip joint is replaced by a prosthetic implant. It is symptomatic osteoarthritis, including moderate and severe generally conducted to relieve arthritis pain or treat forms (WHO, 2014[1]). severe physical joint damage following hip fracture. Age is the strongest predictor of the development and Knee replacement is a surgical procedure to replace progression of osteoarthritis. It is more common in women, the weight-bearing surfaces of the knee joint in order increasing after the age of 50 especially in the hand and to relieve the pain and disability of osteoarthritis. It knee. Other risk factors include obesity, physical inactivity, may also be performed for other knee diseases such as smoking, excessive alcohol consumption and injuries. rheumatoid arthritis. While joint replacement surgery is mainly carried out Classification systems and registration practices vary among people aged 60 and over, it can also be performed on across countries, which may affect the comparability people at younger ages. of the data. While most countries include both total In 2017, Germany, Austria, Switzerland, Finland, and partial hip replacement, some countries only Luxembourg and Belgium were among the countries with include total replacement. In Ireland, Mexico, New the highest rates for hip and knee replacement (Figure 9.12 Zealand and the United Kingdom, the data only and Figure 9.13). The OECD averages are 182 per 100 000 include activities in publicly funded hospitals, thereby population for hip replacement, and 135 per 100 000 for knee underestimating the number of total procedures replacement. Mexico, Portugal, Israel, Ireland and Korea presented here (for example, approximately 15% of all have low hip and knee replacement rates. Differences in hospital activity in Ireland is undertaken in private population structure may explain part of this variation hospitals). Data for Portugal relate only to public across countries, and age standardisation reduces it to some hospitals on the mainland. Data for Spain only partly extent. Nevertheless, large differences persist and the include activities in private hospitals. country ranking does not change significantly after age standardisation (McPherson, Gon and Scott, 2013[2]). National averages can mask important variation in hip and knee replacement rates within countries. In Australia, References Canada, Germany, France and Italy, the rate of knee [2] McPherson, K., G. Gon and M. Scott (2013), “International replacement is more than twice as high in some regions Variations in a Selected Number of Surgical Procedures”, than others, even after age-standardisation (OECD, 2014[3]). OECD Health Working Papers, No. 61, OECD Publishing, Paris, Alongside the number of operations, the quality of hip and https://dx.doi.org/10.1787/5k49h4p5g9mw-en. knee surgery (see indicator on “Hip and knee surgery” in [3] OECD (2014), Geographic Variations in Health Care: What Do We Chapter 6) and waiting times (see indicator on “Waiting Know and What Can Be Done to Improve Health System times for elective surgery” in Chapter 5) are also critical for Performance?, OECD Health Policy Studies, OECD Publishing, patients. Paris, https://dx.doi.org/10.1787/9789264216594-en. Since 2000, the number of hip and knee replacements has [4] Wallace, I. et al. (2017), “Knee osteoarthritis has doubled in increased rapidly in most OECD countries (Figure 9.14 and prevalence since the mid-20th century”, Proceedings of the Figure 9.15). On average, hip replacement rates increased by National Academy of Sciences, Vol. 114/35, pp. 9332-9336, http:// 30% between 2007 and 2017 and knee replacement rates by dx.doi.org/10.1073/pnas.1703856114. 40%. This aligns with the rising incidence and prevalence of [1] WHO (2014), “Chronic Rheumatic Conditions”, Fact Sheet, osteoarthritis, caused by ageing populations and growing http://www.who.int/chp/topics/rheumatic/en/. 198 HEALTH AT A GLANCE 2019 © OECD 2019 9. HEALTH CARE ACTIVITIES Hip and knee replacement Figure 9.12. Hip replacement surgery, 2017 (or nearest year) Figure 9.13. Knee replacement surgery, 2017 (or nearest year) Germany 309 Switzerland 307 Switzerland 251 Austria 286 Austria 227 Belgium 274 Luxembourg 226 Finland 271 Finland 224 Norway 252 Germany 223 France 248 Australia 213 Denmark 248 Belgium 210 Sweden 240 Canada 191 Netherlands 238 France 175 Iceland 224 Denmark 163 Slovenia 200 Netherlands 159 Australia 195 United Kingdom 145 Luxembourg 194 Korea 136 Lithuania 194 OECD31 135 Czech Republic 189 Czech Republic 132 Italy 183 Sweden 132 OECD32 182 Lithuania 130 United Kingdom 181 Spain 130 Poland 160 Slovenia 128 Canada 159 Norway 126 New Zealand 158 Italy 124 Latvia 157 New Zealand 111 Estonia 156 Slovak Republic 106 Hungary 139 Latvia 103 Slovak Republic 136 Hungary 85 Ireland 130 Estonia 82 Spain 116 Israel 66 Portugal 91 Poland 64 Israel 67 Portugal 62 Korea 56 Ireland 49 Chile 46 Mexico 9 Chile 19 Mexico 4 0 50 100 150 200 250 300 350 0 50 100 150 200 250 300 Per 100 000 population Per 100 000 population Source: OECD Health Statistics 2019. Source: OECD Health Statistics 2019. StatLink 2 https://doi.org/10.1787/888934017842 StatLink 2 https://doi.org/10.1787/888934017861 Figure 9.14. Hip replacement surgery trends in selected Figure 9.15. Knee replacement surgery trends in selected OECD countries, 2007-17 OECD countries, 2007-17 Canada Germany Italy Belgium France Hungary Sweden OECD30 Slovenia OECD29 Per 100 000 population Per 100 000 population 350 250 300 200 250 150 200 100 150 50 100 0 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Source: OECD Health Statistics 2019. Source: OECD Health Statistics 2019. StatLink 2 https://doi.org/10.1787/888934017880 StatLink 2 https://doi.org/10.1787/888934017899 HEALTH AT A GLANCE 2019 © OECD 2019 199 From: Health at a Glance 2019 OECD Indicators Access the complete publication at: https://doi.org/10.1787/4dd50c09-en Please cite this chapter as: OECD (2019), “Hip and knee replacement”, in Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris. DOI: https://doi.org/10.1787/2fc83b9a-en This work is published under the responsibility of the Secretary-General of the OECD. The opinions expressed and arguments employed herein do not necessarily reflect the official views of OECD member countries. This document, as well as any data and map included herein, are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area. Extracts from publications may be subject to additional disclaimers, which are set out in the complete version of the publication, available at the link provided. The use of this work, whether digital or print, is governed by the Terms and Conditions to be found at http://www.oecd.org/termsandconditions..
Load more

Recommended publications
  • Amorphous Carbon Coatings for Total Knee Replacements—Part II: Tribological Behavior
    polymers Article Amorphous Carbon Coatings for Total Knee Replacements—Part II: Tribological Behavior Benedict Rothammer 1,* , Max Marian 1,* , Kevin Neusser 1, Marcel Bartz 1, Thomas Böhm 2 , Sebastian Krauß 3, Stefan Schroeder 4, Maximilian Uhler 4 , Simon Thiele 2,5 , Benoit Merle 3 , Jan Philippe Kretzer 4 and Sandro Wartzack 1 1 Engineering Design, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Martensstr. 9, 91058 Erlangen, Germany; [email protected] (K.N.); [email protected] (M.B.); [email protected] (S.W.) 2 Forschungszentrum Jülich GmbH, Helmholtz-Institute Erlangen-Nürnberg for Renewable Energy, Cauerstr. 1, 91058 Erlangen, Germany; [email protected] (T.B.); [email protected] (S.T.) 3 Department of Materials Science & Engineering, Interdisciplinary Center for Nanostructured Films (IZNF) Institute I, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Cauerstr. 3, 91058 Erlangen, Germany; [email protected] (S.K.); [email protected] (B.M.) 4 Laboratory of Biomechanics and Implant Research, Clinic for Orthopedics and Trauma Surgery, Heidelberg University Hospital, Schlierbacher Landstr. 200a, 69118 Heidelberg, Germany; [email protected] (S.S.); [email protected] (M.U.); [email protected] (J.P.K.) 5 Department of Chemical and Biological Engineering, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Egerlandstr. 3, 91058 Erlangen, Germany * Correspondence: [email protected] (B.R.); [email protected] (M.M.) Citation: Rothammer, B.; Marian, M.; Neusser, K.; Bartz, M.; Böhm, T.; Abstract: Diamond-like carbon coatings may decrease implant wear, therefore, they are helping to Krauß, S.; Schroeder, S.; Uhler, M.; reduce aseptic loosening and increase service life of total knee arthroplasties (TKAs).
    [Show full text]
  • A Pilot Clinical Study of Hyperacute Serum Treatment in Osteoarthritic Knee Joint: Cytokine Changes and Clinical Effects
    Article A Pilot Clinical Study of Hyperacute Serum Treatment in Osteoarthritic Knee Joint: Cytokine Changes and Clinical Effects Isabel Olmos Calvo 1,* , Eszter Fodor 2 , Dorottya Kardos 3, István Hornyák 3, Adél Hinsenkamp 3, Olga Kuten-Pella 1 , Zsuzsanna Gyevnár 2,Gábor Erdélyi 4, Tamás Bárdos 4, Tamás Mirkó Paukovits 4, Krisztián Magos 4, György Béres 4, Stefan Nehrer 5 and Zsombor Lacza 2,3 1 OrthoSera GmbH, Dr. Karl-Dorrek-Straße 23-29, 3500 Krems an der Donau, Austria; [email protected] 2 Department of Sport Physiology, University of Physical Education, 44 Alkotás utca, 1123 Budapest, Hungary; [email protected] (E.F.); [email protected] (Z.G.); [email protected] (Z.L.) 3 Institute of Translational Medicine, Semmelweis University, 26 Üllöi utca, 1085 Budapest, Hungary; [email protected] (D.K.); [email protected] (I.H.); [email protected] (A.H.) 4 Kastélypark Klinika, 15 Hajdú utca, 2890 Tata, Hungary; [email protected] (G.E.); [email protected] (T.B.); [email protected] (T.M.P.); [email protected] (K.M.); [email protected] (G.B.) 5 Center for Regenerative Medicine, Danube University, Dr. Karl-Dorrek-Straße 30, 3500 Krems an der Donau, Austria; [email protected] * Correspondence: [email protected] Abstract: The serum fraction of platelet-rich fibrin (hyperacute serum) has been shown to improve Citation: Olmos Calvo, I.; Fodor, E.; cartilage cell proliferation in in vitro osteoarthritic knee joint models. We hypothesize that hyper- Kardos, D.; Hornyák, I.; Hinsenkamp, acute serum may be a potential regenerative therapeutic for osteoarthritic knees.
    [Show full text]
  • Efficacy and Safety of Eltenac Gel in the Treatment of Knee Osteoarthritis B
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Osteoarthritis and Cartilage (2001) 9, 273–280 © 2001 OsteoArthritis Research Society International 1063–4584/01/030273+08 $35.00/0 doi:10.1053/joca.2000.0385, available online at http://www.idealibrary.com on Efficacy and safety of eltenac gel in the treatment of knee osteoarthritis B. Ottillinger*, B. Go¨mo¨r†, B. A. Michel‡, K. Pavelka§, W. Beck\ and U. Elsasser¶ *Consultant, Foehrenstrasse 12, 85649 Hofolding, Germany; formerly Department of Medical Affairs and Drug Safety, Sankyo Pharma GmbH, 81366 Munich, Germany †National Institute for Rheumatology and Physiotherapy, Frankel Leo´ut 17–19, 1525 Budapest, Hungary ‡Department of Rheumatology and Institute for Physical Medicine, Universita¨tsspital, Gloriastrasse 25, 8091 Zurich, Switzerland §National Institute for Rheumatology, Na slupi 4, 12850 Prague 2, Czech Republic \Orthopedic Practice, Seligenthaler Strasse 8, 84034 Landshut, Germany ¶Department of Medical Affairs and Drug Safety, Sankyo Pharma GmbH, 81366 Munich, Germany Summary Objective: A double-blind, placebo-controlled dose-finding study was performed in 237 patients with predominantly unilateral knee osteoarthritis (OA) evaluating efficacy and safety of a new topical NSAID. Design: The patients applied 3 g tid eltenac gel 0.1%, 0.3%, 1% or placebo gel over a period of 4 weeks. The patients were supplied with paracetamol tablets as an escape analgesic. Primary efficacy end-point was mean global pain in the week preceding the examinations, evaluated on a visual analog scale (VAS). Secondary criteria were Lequesne’s score ISK, Jezek score, muscle strength and dolorimeter measurements, walking time, clinical examination results of the knee joint and patient’s and investigator’s overall efficacy estimates.
    [Show full text]
  • Orthokine Therapy Important Information Vers03 EN
    ORTHOKINE®-THERAPY Important information Version 03 / June 2014 / Orthogen Lab Services GmbH page 1 of 19 Introduction Orthokine ® (autologous conditioned serum or ACS) is a special serum from the patients own blood, which features a significantly higher concentration of signaling proteins, especially Interleukin-1 receptor antagonist (IL-1Ra) and different growth factors. The initial idea to develop the Orthokine ®-therapy is based on the fact that Interleukin-1 (IL-1; a messenger of the immune system) plays an important role in cartilage degradation, nerve root inflammation and pain. The opponent of IL-1, IL-1Ra, is a natural inhibitor of IL-1. Particular immune cells in the blood of a patient are capable of releasing IL-1Ra in large quantities. During the processing of Orthokine ® those cells are triggered to do so as well as several growth factors, which play an important role in connective tissue repair. Orthokine ®-therapy was developed during the 1990s by Prof. (USA) Peter Wehling in Düsseldorf, Germany for the treatment of orthopaedic diseases of humans and also animals. This therapy is successfully used by many specialists in almost 30 countries around the world. About 100,000 patients and 60,000 horses have been treated with this special biological therapy. There are more than 30 publications on the efficacy, safety and mode of action of Orthokine ®. The effectiveness and safety of the Orthokine ®-therapy has been demonstrated by clinical data from numerous physicians around the world and by results of randomised, controlled, double-blind clinical studies, published in “peer reviewed“ journals. These data have shown that Orthokine ®-therapy has significant advantages related to effectiveness and safety in comparison to a number of other recommended treatments of osteoarthritis.
    [Show full text]
  • Downloads/Usermanual/MVN User Manual.Pdf (Accessed on 1 May 2021)
    applied sciences Article Kinect Azure–Based Accurate Measurement of Dynamic Valgus Position of the Knee—A Corrigible Predisposing Factor of Osteoarthritis Ádám Uhlár 1,* , Mira Ambrus 1 ,Márton Kékesi 1, Eszter Fodor 1 ,László Grand 2,3, Gergely Szathmáry 2, Kristóf Rácz 4 and Zsombor Lacza 1,* 1 Research Center for Sports Physiology, University of Physical Education, 1123 Budapest, Hungary; [email protected] (M.A.); [email protected] (M.K.); [email protected] (E.F.) 2 Faculty of Information Technology and Bionics, Pázmány Péter Catholic University, 1083 Budapest, Hungary; [email protected] (L.G.); [email protected] (G.S.) 3 Neurology and Neurosurgery, The Johns Hopkins Hospital, 855 N Wolfe St., Baltimore, MD 21205, USA 4 Department of Mechatronics, Optics and Mechanical Engineering Informatics, Budapest University of Technology and Economics, 1111 Budapest, Hungary; [email protected] * Correspondence: [email protected] (Á.U.); [email protected] (Z.L.); Tel.: +36-70-678-38-98 (Á.U.) Featured Application: Lateral disposition of the knee under load in the single-leg squat (SLS) test is widely used for screening functional instabilities of the knee under load, which is asso- ciated with elevated risk of lower limb injuries and early onset of osteoarthritis. We identified that approximation of the Quadriceps angle at the lowest point of squat is error-prone and not suitable for comparing patients or monitoring progress, as it is highly dependent on squat depth and muscle strength. The current study shows that the Kinect Azure–based Dynaknee software Citation: Uhlár, Á.; Ambrus, M.; is able to simultaneously measure squat depth and the dynamic valgus position of the knee.
    [Show full text]
  • WAITING TIMES POLICIES in the HEALTH SECTOR What Works? SECTION 1
    WAITING TIMES POLICIES IN THE HEALTH SECTOR What works? SECTION 1 WAITING TIMES FOR HEALTH CARE: A CONCEPTUAL FRAMEWORK Long waiting times for health services are a prominent health policy issue in many OECD countries. Emergency Currently a national Elective Primary health Outpatient Long-term Country departments/ Cancer care strategy to reduce surgery care (GPs) speciality care care surgery w aiting times Australia X X X X X X Yes Austria X Yes Canada X X X X X X Yes Czech Republic X X X No Denmark X X X X Yes England X X X X X X Yes Finland X X X X X Yes Germany X X X No Iceland X X X X No Ireland X X X X X Yes Israel X X X X X No Netherlands X X X No Norw ay X X X X X No New Zealand X X X X Yes Poland X X X X No Portugal X X X X X X Yes Scotland X X X X X Yes Slovak Rep X Yes Slovenia X X X X Yes Spain X Yes Sw eden X X X X X Yes Turkey X X X X X X Yes Source: OECD (2013). Annexe 1A1. Waiting Times Policies in the Health Sector. What Works? Paris, OECD Publishing Why do some OECD countries experience waiting times and others don’t? Strong negative association between waiting times and the availability of curative care beds. Curative care beds per 1 000 population and percentage waiting four months or more for elective surgery, 2010 Linear (With Germany) Linear (Without Germany) 30 CAN 25 SWE NOR 20 UK AUS 15 Corr=-0.55, p-value=0.10 10 NZL SWITZ Corr=-0.67, p-value=0.02 elective surgery 5 USA FRA NLD GER 0 Percentage four waited months or more for 0 1 2 3 4 5 6 Curative care beds, per 1 000 population Source: OECD (2012), OECD Health Data 2012, OECD Publishing, Paris, DOI: 10.1787/health-data-en; and C.
    [Show full text]
  • 4.7. Hip and Knee Replacement
    4. HEALTH CARE ACTIVITIES 4.7. Hip and knee replacement Significant advances in surgical treatment have provided ment increased by over 25% between 2000 and 2009. The effective options to reduce the pain and disability associated growth rate was even higher for knee replacement, nearly with certain musculoskeletal conditions. Joint replacement doubling over the past decade. In the United States, both surgery (hip and knee replacement) is considered the most hip replacement and knee replacement rates nearly effective intervention for severe osteoarthritis, reducing doubled since 2000. In Denmark, while the hip replacement pain and disability and restoring some patients to near- rate increased by only about 20% between 2000 and 2009, normal function. the knee replacement rate almost tripled. The growth rate Ostheoarthritis is one of the ten most disabling diseases in was more modest in other countries such as France and developed countries (WHO, 2010b). Worldwide estimates Israel. are that 10% of men and 18% of women aged over 60 years The growing volume of hip and knee replacement is have symptomatic osteoarthritis, including moderate and contributing to health expenditure growth as these are severe forms. Age is the strongest predictor of the develop- expensive interventions. In 2007, the average estimated ment and progression of osteoarthritis. It is more common price of a knee replacement was nearly USD 15 000 in the in women, increasing after the age of 50 especially in the United States and Australia, USD 12 000 in France, and about hand and knee. Other risk factors include obesity, physical USD 10 000 in Canada, Germany and Sweden.
    [Show full text]
  • Hungary Country Health Profile 2017
    State of Health in the EU Hungary Country Health Profile 2017 European on Health Systems and Policies a partnership hosted by WHO The Country Health Profile series Contents The State of Health in the EU profiles provide a concise and 1 • HIGHLIGHTS 1 policy-relevant overview of health and health systems in the EU 2 • HEALTH IN HUNGARY 2 Member States, emphasising the particular characteristics and 3 • RISK FACTORS 4 challenges in each country. They are designed to support the efforts of Member States in their evidence-based policy making. 4 • THE HEALTH SYSTEM 6 5 • PERFORMANCE OF THE HEALTH SYSTEM 8 The Country Health Profiles are the joint work of the OECD and 5.1 Effectiveness 8 the European Observatory on Health Systems and Policies, in 5.2 Accessibility 11 cooperation with the European Commission. The team is grateful for the valuable comments and suggestions provided by Member 5.3 Resilience 13 States and the Health Systems and Policy Monitor network. 6 • KEY FINDINGS 16 Data and information sources The data and information in these Country Health Profiles are The calculated EU averages are weighted averages of the based mainly on national official statistics provided to Eurostat 28 Member States unless otherwise noted. and the OECD, which were validated in June 2017 to ensure the highest standards of data comparability. The sources and To download the Excel spreadsheet matching all the methods underlying these data are available in the Eurostat tables and graphs in this profile, just type the following Database and the OECD health database. Some additional data StatLinks into your Internet browser: also come from the Institute for Health Metrics and Evaluation http://dx.doi.org/10.1787/888933593589 (IHME), the European Centre for Disease Prevention and Control (ECDC), the Health Behaviour in School-Aged Children (HBSC) surveys and the World Health Organization (WHO), as well as other national sources.
    [Show full text]